MAPK8 and colitis: The experimental studies of colitis carried out using specific inhibitors of JNK (inhibitor SP600125), ERK (inhibitor U0126), and p38 (inhibitor SB203580) have shown protective effects by ameliorating proinflammatory cytokine release [34, 36, 37].